



Technical Report No. 83

Virus Contamination in Biomanufacturing: Risk Mitigation, Preparedness, and Response

A large, abstract graphic design is centered at the bottom of the page. It consists of several overlapping, curved, light-gray shapes that resemble stylized leaves or petals. The design is symmetrical and covers the lower third of the page.

www.pda.org/store

PDA Virus Contamination in Biomanufacturing: Risk Mitigation, Preparedness, and Response Technical Report Team

Authors and Contributors

Houman Dehghani, Ph.D., Allogene Therapeutics (Co-Lead)

Robert Kiss, Ph.D., Sutro Biopharma (Co-Lead)

Marshall Dinowitz, Sc.D., Pacific BioDevelopment (Retired)

Jim Gilbert, Ph.D., Consultant

Linda Hendricks, Johnson & Johnson

Rajesh Krishnan, Ph.D., Oncternal Therapeutics

Yuling Li, Ph.D., Apollomics Inc.

Mark Lutgen, KBI Biopharma

Eric Mundhenke, KBI Biopharma

Anne Stokes, Ph.D., GlaxoSmithKline PLC

Dominick Vacante, Ph.D., Janssen R&D, LLC

Michael Wiebe, Ph.D., Quantum Consulting, LLC

To order this document, please visit: go.pda.org/TR83

Virus Contamination in Biomanufacturing: Risk Mitigation, Preparedness, and Response

Technical Report No. 83

ISBN: 978-1-945584-10-7
© 2019 Parenteral Drug Association, Inc.
All rights reserved.



Table of Contents

| | | | |
|--|----------|--|-----------|
| 1.0 INTRODUCTION | 1 | 4.0 PREPARATION FOR A VIRUS CONTAMINATION .. | 18 |
| 1.1 Purpose | 1 | 4.1 Virus Contamination Response Plan | 18 |
| 1.2 Scope | 2 | 4.2 Investigation Management Structure and Leadership | 19 |
| 2.0 GLOSSARY | 2 | 4.3 Response Plan Elements..... | 19 |
| 2.1 Abbreviations..... | 3 | | |
| 3.0 RISK MITIGATION..... | 3 | 5.0 RESPONSE TO A VIRUS CONTAMINATION | 24 |
| 3.1 Risk Analysis and Management..... | 3 | 5.1 Detection of Contamination | 24 |
| 3.1.1 Raw Materials..... | 4 | 5.1.1 Cell Substrate | 25 |
| 3.1.2 Assessment of High-Risk Raw Materials | 4 | 5.1.2 Raw Materials..... | 25 |
| 3.1.3 Replacement of High-Risk Materials..... | 5 | 5.1.3 Cell Culture Process..... | 25 |
| 3.1.4 Control of the Raw Material Source | 5 | 5.2 Identification of Contaminant | 26 |
| 3.1.5 Cell Substrate..... | 7 | 5.3 Containment, Inactivation and Decontamination | 26 |
| 3.1.6 Facility | 8 | 5.3.1 Components of Facility Decontamination and Cleanup | 27 |
| 3.1.7 Use of a Risk Management Tool | 8 | 5.4 Root Cause Analysis, Corrective & Preventive Actions, and Facility Restart | 29 |
| 3.1.8 Example of Risk Assessment of mAb Produced by CHO Cells..... | 9 | 5.5 Product and Supply Impact | 30 |
| 3.2 Mitigation | 12 | | |
| 3.2.1 Facility and Equipment Considerations | 12 | 6.0 CONCLUSIONS..... | 31 |
| 3.2.2 Operational Practices..... | 14 | | |
| 3.3 Barriers to Contamination in the Cell Culture Processing Areas..... | 15 | 7.0 REFERENCES..... | 31 |
| 3.3.1 Treatment of High-Risk Raw Materials | 15 | | |
| 3.3.2 Testing of Cell Banks and Raw Materials | 16 | | |
| 3.3.3 Development and Qualification of Robust, State-of-the-Art Methodologies for In-Process Viral Testing | 17 | | |

FIGURES AND TABLES INDEX

| | | | |
|----------------------|--|----------------------|--|
| Figure 1.1-1 | Virus Contamination Risk Management Approach..... | Table 3.1.8-3 | Worked Example for Initial Risk Evaluation |
| | 1 | | 10 |
| Table 3.1.8-1 | Scoring System for Probability and Impact (Severity) of Risk | Table 3.1.8-4 | Example of a Portion of a Risk Assessment for Manufacturing Facility |
| | 9 | | 11 |
| Table 3.1.8-2 | Guideline (Grid) for Probability and Impact of Risk..... | Table 4.3-1 | Contamination Response Plan Elements |
| | 10 | | 20 |



Bethesda Towers
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org